

## **MEA Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030**

Market Report | 2022-11-01 | 219 pages | Data Bridge Market Research

### **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

### **Report description:**

The Middle East and Africa melanoma cancer diagnostics market is projected to register a substantial CAGR of 5.8% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Melanoma Cancer Diagnostics Market, By Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution channel (Direct Tender and Retail Sales), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the Middle East and Africa melanoma cancer diagnostics market are:

- Increase in the prevalence of melanoma cancer
- Rising preference for preventive health check-ups

Market Players:

Some of the major players operating in the Middle East and Africa melanoma cancer diagnostics market are:

- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Agilent Technologies, Inc.
- QIAGEN
- F. Hoffman-La Roche Ltd
- Abbott
- Myriad Genetics, Inc.
- VERISKIN INC.
- Illumina Inc

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- bioMerieux SA
- NanoString

## **Table of Contents:**

### TABLE OF CONTENTS

1 INTRODUCTION	48
1.1 OBJECTIVES OF THE STUDY	48
1.2 MARKET DEFINITION	48
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET	48
1.4 LIMITATIONS	50
1.5 MARKETS COVERED	50
2 MARKET SEGMENTATION	53
2.1 MARKETS COVERED	53
2.2 GEOGRAPHICAL SCOPE	54
2.3 YEARS CONSIDERED FOR THE STUDY	55
2.4 CURRENCY AND PRICING	55
2.5 DBMR TRIPOD DATA VALIDATION MODEL	56
2.6 MULTIVARIATE MODELLING	60
2.7 PRODUCT TYPE LIFELINE CURVE	60
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	61
2.9 DBMR MARKET POSITION GRID	62
2.10 MARKET END USER COVERAGE GRID	63
2.11 VENDOR SHARE ANALYSIS	64
2.12 SECONDARY SOURCES	65
2.13 ASSUMPTIONS	65
3 EXECUTIVE SUMMARY	66
4 PREMIUM INSIGHTS	68
4.1 PESTEL'S MODEL	69
4.2 PORTER'S FIVE FORCES MODEL	70
5 EPIDEMIOLOGY	71
6 INDUSTRY INSIGHTS	72
6.1 DEMOGRAPHIC TRENDS	72
6.2 KEY PRICING STRATEGIES	73
6.2.1 PRODUCT INNOVATION	73
6.2.2 CONSUMER AWARENESS	73
6.2.3 A VAST NETWORK OF DISTRIBUTION	73
6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS	74
6.2.5 OTHERS	74
6.3 KEY PATIENT ENROLLMENT STRATEGIES	74
6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGNOSTIC PRODUCTS	74
6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP	74
6.3.3 EDUCATE AND COMMUNICATE	75
6.3.4 IMPROVING DIAGNOSIS SEEKING RATE	75
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES	75

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

7	MARKET OVERVIEW	77
7.1	DRIVERS	79
7.1.1	GROWING PREVALENCE OF MELANOMA CANCER	79
7.1.2	RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS	80
7.1.3	NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS	81
7.1.4	INCREASING AWARENESS REGARDING MELANOMA CANCER	82
7.2	RESTRAINTS	82
7.2.1	LACK OF SKILLED AND CERTIFIED PROFESSIONALS	82
7.2.2	HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS	83
7.3	OPPORTUNITIES	83
7.3.1	INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT	83
7.3.2	GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS	84
7.3.3	INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS	85
7.3.4	GROWING DEMAND FOR BETTER QUALITY HEALTHCARE	85
7.4	CHALLENGES	86
7.4.1	STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS	86
7.4.2	RADIATION RISKS FROM IMAGING TESTS	86
8	MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE	87
8.1	OVERVIEW	88
8.2	INSTRUMENTS	91
8.2.1	IMAGING INSTRUMENTS	92
8.2.1.1	ULTRASOUND SYSTEMS	92
8.2.1.2	MRI SYSTEMS	92
8.2.1.3	CT SYSTEMS	92
8.2.1.4	OTHERS	93
8.2.2	BIOPSY INSTRUMENTS	93
8.2.3	PATHOLOGY-BASED INSTRUMENTS	93
8.2.3.1	PCR INSTRUMENTS	93
8.2.3.2	CELL PROCESSORS	93
8.2.3.3	SLIDE STAINING SYSTEMS	93
8.2.3.4	TISSUE PROCESSING SYSTEMS	94
8.2.3.5	OTHER PATHOLOGY-BASED INSTRUMENTS	94
8.3	CONSUMABLES & ACCESSORIES	94
8.3.1	KITS	95
8.3.1.1	PCR KITS	95
8.3.1.2	NUCLEIC ACID ISOLATION KITS	95
8.3.1.3	DNA POLYMERASE KITS	95
8.3.1.4	OTHERS	96
8.3.2	PROBES	96
8.3.2.1	Q FISH	96
8.3.2.2	FLOW FISH	96
8.3.2.3	OTHERS	96
8.3.3	REAGENTS	96
8.3.3.1	ASSAYS	97
8.3.3.2	BUFFERS	97
8.3.3.3	PRIMERS	97

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

8.3.3.4 OTHERS	97
8.3.4 OTHER CONSUMABLES	97
8.4 OTHERS	97
9 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE	99
9.1 OVERVIEW	100
9.2 IMAGING TEST	103
9.2.1 ULTRASOUND	104
9.2.2 MRI	104
9.2.3 CHEST X-RAY	104
9.2.4 LYMPHOSCINTIGRAPHY	105
9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN	105
9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN	105
9.2.7 OTHERS	105
9.3 BIOPSY	105
9.3.1 OPTICAL BIOPSY	106
9.3.2 EXCISIONAL BIOPSY	106
9.3.3 INCISIONAL BIOPSY	106
9.3.4 SHAVE BIOPSY	107
9.3.5 PUNCH BIOPSY	107
9.3.6 OTHERS	107
9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS	107
9.4.1 S100 PROTEIN FAMILY BIOPSY	108
9.4.2 MELAN-A	108
9.4.3 PMEL/PMEL17/SILV/GP100	108
9.4.4 TYROSINASE	108
9.4.5 MITF	108
9.4.6 SM5-1	108
9.4.7 CSPG4/HMW-MAA	108
9.5 BIOMARKER TEST	109
9.5.1 BRAF MUTATION TEST	110
9.5.2 NRAS MUTATION TEST	110
9.5.3 CKIT TEST	110
9.5.4 OTHERS	110
9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS	110
9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS	111
9.8 OTHERS	112
10 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER	113
10.1 OVERVIEW	114
10.2 HOSPITALS	117
10.3 ASSOCIATED LABS	118
10.4 DIAGNOSTIC IMAGING CENTERS	118
10.5 INDEPENDENT DIAGNOSTIC LABORATORIES	119
10.6 CANCER RESEARCH INSTITUTES	120
10.7 OTHERS	121
11 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL	122
11.1 OVERVIEW	123
11.2 DIRECT TENDER	126

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

11.3 RETAIL SALES	126
12 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION	128
12.1 MIDDLE EAST AND AFRICA	129
12.1.1 SOUTH AFRICA	139
12.1.2 EGYPT	144
12.1.3 SAUDI ARABIA	149
12.1.4 U.A.E.	154
12.1.5 OMAN	159
12.1.6 KUWAIT	164
12.1.7 QATAR	169
12.1.8 BAHARAIN	174
12.1.9 REST OF MIDDLE EAST AND AFRICA	179
13 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE	180
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA	180
14 SWOT ANALYSIS	181
15 COMPANY PROFILE	182
15.1 ABBOTT	182
15.1.1 COMPANY SNAPSHOT	182
15.1.2 REVENUE ANALYSIS	182
15.1.3 COMPANY SHARE ANALYSIS	183
15.1.4 PRODUCT PORTFOLIO	183
15.1.5 RECENT DEVELOPMENTS	183
15.2 ILLUMINA, INC.	184
15.2.1 COMPANY SNAPSHOT	184
15.2.2 REVENUE ANALYSIS	184
15.2.3 COMPANY SHARE ANALYSIS	185
15.2.4 PRODUCT PORTFOLIO	185
15.2.5 RECENT DEVELOPMENT	185
15.3 BIOMERIEUX SA	186
15.3.1 COMPANY SNAPSHOT	186
15.3.2 REVENUE ANALYSIS	186
15.3.3 COMPANY SHARE ANALYSIS	187
15.3.4 PRODUCT PORTFOLIO	187
15.3.5 RECENT DEVELOPMENTS	187
15.4 THERMO FISHER SCIENTIFIC INC.	188
15.4.1 COMPANY SNAPSHOT	188
15.4.2 REVENUE ANALYSIS	188
15.4.3 COMPANY SHARE ANALYSIS	189
15.4.4 PRODUCT PORTFOLIO	189
15.4.5 RECENT DEVELOPMENT	189
15.5 F. HOFFMANN-LA ROCHE LTD.	190
15.5.1 COMPANY SNAPSHOT	190
15.5.2 REVENUE ANALYSIS	190
15.5.3 COMPANY SHARE ANALYSIS	191
15.5.4 PRODUCT PORTFOLIO	191
15.5.5 RECENT DEVELOPMENT	191
15.6 AGILENT TECHNOLOGIES, INC.	192

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

15.6.1 COMPANY PROFILE	192
15.6.2 REVENUE ANALYSIS	192
15.6.3 PRODUCT PORTFOLIO	193
15.6.4 RECENT DEVELOPMENT	193
15.7 AMLO BIOSCIENCES LIMITED	194
15.7.1 COMPANY PROFILE	194
15.7.2 PRODUCT PORTFOLIO	194
15.7.3 RECENT DEVELOPMENT	194
15.8 CASTLE BIOSCIENCES INC	195
15.8.1 COMPANY SNAPSHOT	195
15.8.2 REVENUE ANALYSIS	195
15.8.3 PRODUCT PORTFOLIO	196
15.8.4 RECENT DEVELOPMENT	196
15.9 DAMAE MEDICAL	197
15.9.1 COMPANY PROFILE	197
15.9.2 PRODUCT PORTFOLIO	197
15.9.3 RECENT DEVELOPMENT	197
15.10 DERMLITE.	198
15.10.1 COMPANY PROFILE	198
15.10.2 PRODUCT PORTFOLIO	198
15.10.3 RECENT DEVELOPMENTS	198
15.11 DERMASENSOR	199
15.11.1 COMPANY PROFILE	199
15.11.2 PRODUCT PORTFOLIO	199
15.11.3 RECENT DEVELOPMENT	199
15.12 DERMTECH	200
15.12.1 COMPANY SNAPSHOT	200
15.12.2 REVENUE ANALYSIS	200
15.12.3 PRODUCT PORTFOLIO	201
15.12.4 RECENT DEVELOPMENT	201
15.13 INIVATA LTD.	202
15.13.1 COMPANY PROFILE	202
15.13.2 PRODUCT PORTFOLIO	202
15.13.3 RECENT DEVELOPMENT	202
15.14 MICHAEL DIAGNOSTICS LTD	203
15.14.1 COMPANY SNAPSHOT	203
15.14.2 PRODUCT PORTFOLIO	203
15.14.3 RECENT DEVELOPMENT	203
15.15 MYRIAD GENETICS, INC.	204
15.15.1 COMPANY SNAPSHOT	204
15.15.2 REVENUE ANALYSIS	204
15.15.3 PRODUCT PORTFOLIO	205
15.15.4 RECENT DEVELOPMENT	205
15.16 NANOSTRING	206
15.16.1 COMPANY SNAPSHOT	206
15.16.2 REVENUE ANALYSIS	206
15.16.3 PRODUCT PORTFOLIO	207

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

15.16.4 RECENT DEVELOPMENT	207
15.17 NERACARE GMBH	208
15.17.1 COMPANY PROFILE	208
15.17.2 PRODUCT PORTFOLIO	208
15.17.3 RECENT DEVELOPMENT	208
15.18 SKIN ANALYTICS	209
15.18.1 COMPANY PROFILE	209
15.18.2 PRODUCT PORTFOLIO	209
15.18.3 RECENT DEVELOPMENT	209
15.19 SKYLINEDX	210
15.19.1 COMPANY PROFILE	210
15.19.2 PRODUCT PORTFOLIO	210
15.19.3 RECENT DEVELOPMENTS	210
15.20 VERISKIN INC.	211
15.20.1 COMPANY PROFILE	211
15.20.2 PRODUCT PORTFOLIO	211
15.20.3 RECENT DEVELOPMENTS	211

## MEA Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2022-11-01 | 219 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-08"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com